Biotechnology (183) | Development Agreements (183)

Browse by Company

Allakos Inc. (1)
Altimmune, Inc. (4)
ALX ONCOLOGY HOLDINGS INC (2)
Anixa Biosciences Inc (1)
Apellis Pharmaceuticals, Inc. (2)
Arcturus Therapeutics Holdings Inc. (4)
Atara Biotherapeutics, Inc. (4)
Athenex, Inc. (1)
BIOCRYST PHARMACEUTICALS INC (14)
BIOTIME INC (2)
Bone Biologics Corp (1)
CASI Pharmaceuticals, Inc. (3)
Chelsea Worldwide Inc. (1)
CHIMERIX INC (15)
Conatus Pharmaceuticals Inc. (1)
CONTRAFECT Corp (1)
Corvus Pharmaceuticals, Inc. (1)
Cyclerion Therapeutics, Inc. (1)
DiaMedica Therapeutics Inc. (1)
DYADIC INTERNATIONAL INC (1)
Emerald Bioscience, Inc. (2)
Emergent BioSolutions Inc. (20)
Entasis Therapeutics Holdings Inc. (1)
Evelo Biosciences, Inc. (1)
Exelixis (1)
FIBROGEN INC (1)
FS Development Corp. (5)
FS Development Corp. II (5)
Fusion Pharmaceuticals Inc. (2)
Harpoon Therapeutics, Inc. (3)
HISTOGENICS CORP (1)
HUMANIGEN, INC (1)
iBio, Inc. (2)
ImmunoCellular Therapeutics, Ltd. (1)
Inhibikase Therapeutics, Inc. (2)
Intec Pharma Ltd. (1)
LianBio (1)
Ligand Pharmaceuticals Incorporated (1)
LONGEVERON LLC (2)
Matinas BioPharma Holdings, Inc. (1)
Moderna, Inc. (6)
NORTHWEST BIOTHERAPEUTICS INC (1)
NOVAVAX INC (3)
Omega Therapeutics, Inc. (2)
Orchard Therapeutics plc (1)
Passage BIO, Inc. (1)
Regeneron Pharmaceuticals (1)
Revolution Medicines, Inc. (1)
RHYTHM PHARMACEUTICALS, INC. (2)
RITTER PHARMACEUTICALS INC (1)
Sana Biotechnology, Inc. (1)
SEATTLE GENETICS INC (6)
Social Capital Suvretta Holdings Corp. III (1)
SOPHIRIS BIO INC. (1)
T2 Biosystems, Inc. (8)
Tracon Pharmaceuticals, Inc. (2)
TREVENA INC (1)
Unicycive Therapeutics, Inc. (1)
Vaxcyte, Inc. (6)
VERACYTE, INC. (1)
Vertex Pharmaceuticals Inc (6)
Verve Therapeutics, Inc. (1)
Viela Bio, Inc. (1)
Vir Biotechnology, Inc. (1)
XOMA Corp (1)
ZIOPHARM ONCOLOGY INC (11)

Recent Contracts

Amendment of Solicitation/Modification of Contract, dated as of July 26, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S.... (T2 Biosystems, Inc., Filed With SEC on August 16, 2022)
Fourth Amendment to the Cooperative Research and Development Agreement, dated June 24, 2022, by and between the National Cancer Institute and the Registrant (ZIOPHARM ONCOLOGY INC, Filed With SEC on August 15, 2022)
Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Amendment No. 1 to the Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Statement of Work No. 1 to the Contract Development Manufacture Agreement (NOVAVAX INC, Filed With SEC on August 9, 2022)
Master Services Agreement, dated May 1, 2019, by and between PPD Development, LP and ProKidney (formerly RegenMed (Cayman) Ltd.) (Social Capital Suvretta Holdings Corp. III, Filed With SEC on August 9, 2022)
Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd., dated October 21, 2016, as amended (Vaxcyte, Inc., Filed With SEC on August 8, 2022)
Master Services Agreement for Drug Product Development and Manufacturing between the Registrant and Lonza Ltd., dated March 22, 2022, as amended (Vaxcyte, Inc., Filed With SEC on August 8, 2022)
Amendment No. 13 to Agreement No. HHSO100201600029C, by and between ModernaTX, Inc. and the Biomedical Advanced Research and Development Authority, dated as of March 23, 2022 (Moderna, Inc., Filed With SEC on August 3, 2022)
Thirteenth Amendment to Development and Supply Agreement, effective May 12, 2022 between Seagen Inc. (f/k/a Seattle Genetics, Inc.) and AbbVie Inc. (formerly part of Abbott... (SEATTLE GENETICS INC, Filed With SEC on July 28, 2022)